Rikke Wehner Rasmussen

Ms. Rikke Wehner Rasmussen


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
RRRikke Wehner Rasmussen
Rikke Wehner Rasmussen
JBJaco Botha
Jaco Botha
FPFrederik Prip
Frederik Prip
MSMathilde Sanden
Mathilde Sanden
MNMorten H. Nielsen
Morten H. Nielsen
AHAase Handberg
Aase Handberg
High-resolution flow cytometers (hFCM) are used for the detection of extracellular vesicles (EV) in various biological fluids. Due to the increased sensitivity of hFCM, new artifacts with the potential of interfering with data interpretation are introduced, such as detection of antibody aggregates. The aim of this study was to investigate the extent of aggregates in labels commonly used for the characterization of EVs by hFCM. Furthermore, we aimed to compare the efficacy of centrifugation and filtering treatments to remove aggregates, as well as to quantify the effect of the treatments in reducing aggregates. For this purpose, we labeled phosphate buffered saline (PBS) with fluorescently conjugated protein labels and antibodies after submitting them to 5, 10, or 30 min centrifugation, filtering or washed filtering. We investigated samples by hFCM and quantified the amount of aggregates found in PBS labeled with untreated and pre-treated labels. We found a varying amount of aggregates in all labels investigated, and further that filtering is most efficient in removing all but the smallest aggregates. Filtering protein labels can reduce the extent of aggregates; however, how much remains depends on the specific labels and their combination. Therefore, it is still necessary to include appropriate controls in a hFCM study of EVs.

17 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAnders Askeland
Anders Askeland
JDJavier Donoso-Quezada
Javier Donoso-Quezada
MUMalwina Ulanowska
Malwina Ulanowska
MGMimoza Gjela
Mimoza Gjela
NGNahuel Aquiles García
Nahuel Aquiles García
AHAase Handberg
Aase Handberg
Liver fibrosis is a serious complication of non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MetS), conditions closely linked to obesity. We investigated the levels and dynamics of liver fibrosis biomarkers and liver fat content during personalized weight loss intervention in individuals with obesity, NAFLD, and concomitant MetS (n=30), with assessments at baseline, 1, and 5 months. Liver fat content decreased significantly (p < 0.0001), corresponding with complete resolution of steatosis in 36.7% of the participants, after 1 month of weight loss. Similarily, the fibrosis markers: T1 (p < 0.01), CK18 (p < 0.01), PIIINP (p < 0.0001), TIMP1 (p < 0.001), and MACK3 (p < 0.001) dropped after 1 month. CK18 (p < 0.01) and MACK3 (p < 0.001) further changed from 1 to 5 months, while FNI decreased after 5 months (p < 0.01). Except for CK18, the dynamics of these changes were more pronounced from baseline to 1 month compared with 1 to 5 months. Finally, MACK3 showed promise for explaining T1.Our study underlines the importance of weight loss in swiftly mitigating liver steatosis and supports the integration of non-invasive biomarkers to monitor fibrosis risk in individuals with obesity, NAFLD, and MetS.